Building Flexible, Scalable and Sustainable Cell Therapy Manufacturing Network to Serve Patients

  • Balancing demand and capacity for personalized medicines
  • Optimizing speed, cost and quality
  • Embracing Innovation
  • Enabling Horizontal Collaboration

Robert Zamboldi
Site Head – US Cell & Gene Therapy, Morris Plains

Rob Zamboldi is the Site Head and General Manager of Novartis’ flagship cell processing operation in Morris Plains, NJ providing worldwide supply of novel CAR-T therapies. Rob was instrumental in the ramp up of the first to market CAR-T, Kymriah ® of which more than 7,000 treatments have been supplied from his facility.

Under Rob’s leadership, he oversaw the turnaround from a single product site into a multi-product manufacturing facility, delivering Novartis’ commercial and clinical products as well as securing multiple third-party contracts as a CMO provider.

Rob’s 26-year tenure with Novartis Technical Operations has spanned the globe in the US, Switzerland, and Singapore holding various roles in Operations, Engineering, Quality and External Supply Management. Rob holds a BS in Civil Engineering and a master’s degree in Business Administration.